Cemiplimab and Fianlimab for Nasopharyngeal Cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) designed to help your immune system fight nasopharyngeal cancer. The study focuses on a specific type of nasopharyngeal cancer that is associated with Epstein-Barr virus (EBV), and aims to determine if this combination treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with a biopsy-confirmed diagnosis of non-keratinizing nasopharyngeal cancer
- Your cancer must be at an early to intermediate stage (T1–T2 with specific lymph node involvement) with no spread to distant sites
- Your tumor must test positive for EBV (Epstein-Barr virus), confirmed by a biopsy test
- You must be in good overall health (ECOG performance status 0–1) with adequate blood cell counts, kidney function, and liver function
- You cannot have received prior radiation or chemotherapy for this cancer, and must be evaluated by head and neck surgery, radiation oncology, and medical oncology teams
- You must use reliable birth control if you can become pregnant, and cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.